August 15, 2025JCO oncology advances.

Phase II Study of Peri- and Post-Transplant Ruxolitinib for Patients With Myelofibrosis Receiving Allogeneic Hematopoietic Cell Transplantation

View Full Paper

Ask AI

Bookmark

Authors

GHGabriela HobbsHarvard University HKHaesook T. KimDana-Farber Cancer Institute RHRichard HaoShanghai Jiao Tong University

Discussion

Member takes

Implication

Phase II trial reports 71% graft-versus-host disease-free survival in myelofibrosis patients after transplantation, indicating effective use of ruxolitinib.

Key Points

Ruxolitinib administration resulted in a 71% one-year graft-versus-host disease-free survival for patients with myelofibrosis after transplantation.
During a median follow-up of 27 months, the overall survival rate was 82% with notable low rates of severe acute graft-versus-host disease.
This was a phase II, multicenter clinical trial involving 43 participants receiving reduced-intensity hematopoietic cell transplantation.
The findings highlight the safety and tolerability of ruxolitinib, suggesting it may improve survival outcomes and reduce the risk of complications post-transplant.

Cite This Study

Hobbs et al. (2025) studied this question.

synapsesocial.com/papers/68a365740a429f797332bc65 https://doi.org/10.1200/oa-25-00020

View Full Paper

Ask AI

Bookmark

August 15, 2025JCO oncology advances.

Phase II Study of Peri- and Post-Transplant Ruxolitinib for Patients With Myelofibrosis Receiving Allogeneic Hematopoietic Cell Transplantation

View Full Paper

Ask AI

Bookmark

Authors

GHGabriela HobbsHarvard University HKHaesook T. KimDana-Farber Cancer Institute RHRichard HaoShanghai Jiao Tong University

Discussion

Member takes

Implication

Phase II trial reports 71% graft-versus-host disease-free survival in myelofibrosis patients after transplantation, indicating effective use of ruxolitinib.

Key Points

Ruxolitinib administration resulted in a 71% one-year graft-versus-host disease-free survival for patients with myelofibrosis after transplantation.
During a median follow-up of 27 months, the overall survival rate was 82% with notable low rates of severe acute graft-versus-host disease.
This was a phase II, multicenter clinical trial involving 43 participants receiving reduced-intensity hematopoietic cell transplantation.
The findings highlight the safety and tolerability of ruxolitinib, suggesting it may improve survival outcomes and reduce the risk of complications post-transplant.

Cite This Study

Hobbs et al. (2025) studied this question.

synapsesocial.com/papers/68a365740a429f797332bc65 https://doi.org/10.1200/oa-25-00020

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark